Comparative tolerability of the HMG-CoA reductase inhibitors.
about
Statin-induced lung injury: diagnostic clue and outcomeAn effective assessment of simvastatin-induced toxicity with NMR-based metabonomics approachEffects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover StudyThe potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART)Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience.The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke.Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.Atorvastatin may cause nightmares.Statins: balancing benefits, efficacy and safety.Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era.The rational use of potentially hepatotoxic medications in patients with underlying liver disease.Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia.COX-2 selective inhibitors: analysis of the renal effects.Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature.Fluvastatin and fluvastatin extended release: a clinical and safety profile.Pharmacologic treatment of type 2 diabetic dyslipidemia.Treatment of dyslipidemia in the elderly.Lipid-lowering agents that cause drug-induced hepatotoxicity.Dyslipidemia and lipid-lowering therapy in the elderly.How safe is aggressive statin therapy?Safety and efficacy evaluation of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) in dyslipidemia patients: A pilot prospective cohort clinical study.Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus.Daptomycin: a review 4 years after first approval.New developments in medulloblastoma treatment: the potential of a cyclopamine-lovastatin combination.Lovastatin potentiates the antidepressant efficacy of fluoxetine in rats.The hypolipidemic activity of Ayurvedic medicine, Arogyavardhini vati in Triton WR-1339-induced hyperlipidemic rats: A comparison with fenofibrate.Rhabdomyolysis and acute kidney injury associated with hypothyroidism and statin therapyOxysterols in biological systems: the gastrointestinal tract, liver, vascular wall and central nervous system.A review of perioperative statin therapy for noncardiac surgery.Detecting and treating hyperlipidemia in children with type 1 diabetes mellitus: are standard guidelines applicable to this special population?Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.Drug-drug interaction with statins.The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration.Marketed drugs used for the management of hypercholesterolemia as anticancer armament.Pilot Algorithm Designed to Help Early Detection of HMG-CoA Reductase Inhibitor-Induced Hepatotoxicity.Current and novel therapies for the treatment of nonalcoholic steatohepatitis.Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment.Simvastatin treatment in the SLO syndrome: a safe approach?Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives.
P2860
Q26822368-90FAB916-4227-4031-9E29-EC120302E620Q28477228-DF2BF66A-488D-43D7-93F0-6583B828BF37Q28550267-9EE3FDD9-5FE0-4622-8059-3A076A47E405Q33208345-85055E90-BA12-4CAC-94FE-01940D726E10Q33621245-EE73C326-72D9-4171-A8AF-B18A1F02759EQ33684643-F190B60F-DA94-4986-A89E-62FF9706EA46Q34034752-EBBDB40F-DD53-4D38-869D-4C3F0B3F31B3Q34405404-AAEF1C4B-7FA7-41F4-8143-29600F2B9BFBQ34557057-024786B3-C1D8-4812-B97C-F71B905716CDQ34628565-F652ED44-A6AB-49CA-A385-E96900E181D1Q35194386-E9A43B8C-2242-442E-9B1C-BE0C52FC880BQ35194515-D083D95D-1D59-4AF5-8054-1FBCC0ACF7C8Q35194523-86639112-4FA0-48C0-977D-BCCE23B5DBACQ35194538-1224DBDA-01D0-4870-B89A-7DA61574139AQ35637087-B4BB7963-2F80-4E74-BCE9-26BA05B0CC46Q35879055-02D3E4A6-38D6-47A2-8149-EC362C254751Q35976827-CF2BDA7C-F256-458F-8695-DFD02CB946AFQ36077229-4F03BA55-8FEB-46A2-BCED-FF273BCA8547Q36103339-5DEABCEE-1AAC-4999-A083-52E30C4E619FQ36124897-574549F5-CC35-40A8-9A9B-9EA3FB64B100Q36587418-EB988175-2C46-4159-9B4B-5A729202B574Q36726951-2E05FBA7-A99A-437B-A31E-6DF470A9494BQ36837171-C6AB6A12-E66C-4433-BEA7-3C143F6EE04AQ36972980-10C99FE3-35BD-45DE-A649-6947A09DFC5AQ37071188-93A308D6-2F38-4A6B-B7EC-D8E4B61A009AQ37153469-91F7A7E6-55BC-4920-A286-1E84F5388C43Q37290138-13F65AF5-57CE-4B1F-8AC3-107ACE2AEDA5Q37410211-DC6DD3C5-3D4B-49C9-90F7-8CA3157BB07DQ37638753-96627911-A54E-4533-93BE-257389E0C84EQ37805883-1D1926D8-F7FE-4709-B68A-3738BB966465Q37807503-19DE8207-9F9F-4FFC-8D89-60A385517983Q37855801-789FD0D9-02AF-4CC3-9C39-AD1782E39FC8Q38177333-0B121B14-456C-4D59-9F8E-F27357F968CAQ39348762-561FD360-187E-49CB-B889-231160D77204Q41080847-CBD50E70-235F-4830-A55B-34CFB4049458Q41528115-28E7C26D-281B-4886-B3F1-BB8AB7ABF306Q41832154-CF2C0F01-7A87-4F52-A28F-0B3E1EBB8D98Q43271986-8F10D5F2-E9A6-4940-ADA5-A058203986E2Q44199016-9B77ED1B-A6F4-4669-A1EC-72BA87C9B241Q44739535-36CCDCEB-B312-420F-A9C4-94E95822B1FE
P2860
Comparative tolerability of the HMG-CoA reductase inhibitors.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Comparative tolerability of the HMG-CoA reductase inhibitors.
@ast
Comparative tolerability of the HMG-CoA reductase inhibitors.
@en
Comparative tolerability of the HMG-CoA reductase inhibitors.
@nl
type
label
Comparative tolerability of the HMG-CoA reductase inhibitors.
@ast
Comparative tolerability of the HMG-CoA reductase inhibitors.
@en
Comparative tolerability of the HMG-CoA reductase inhibitors.
@nl
prefLabel
Comparative tolerability of the HMG-CoA reductase inhibitors.
@ast
Comparative tolerability of the HMG-CoA reductase inhibitors.
@en
Comparative tolerability of the HMG-CoA reductase inhibitors.
@nl
P1433
P1476
Comparative tolerability of the HMG-CoA reductase inhibitors.
@en
P2093
G Torre-Amione
J A Farmer
P304
P356
10.2165/00002018-200023030-00003
P577
2000-09-01T00:00:00Z
P6179
1042363218